Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

MDS: unraveling the mystery.

Rizzieri DA.

Blood. 2012 Dec 13;120(25):4906-8. doi: 10.1182/blood-2012-09-452755.

2.

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP.

Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22.

3.

Lenalidomide in myelodysplastic syndrome and multiple myeloma.

Shah SR, Tran TM.

Drugs. 2007;67(13):1869-81. Review.

PMID:
17722955
4.

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.

Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M.

Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28. No abstract available.

5.

Are new agents really making a difference in MDS?

Stone RM.

Best Pract Res Clin Haematol. 2008 Dec;21(4):639-46. doi: 10.1016/j.beha.2008.06.004. Review.

PMID:
19041603
6.

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

Sekeres MA, O'Keefe C, List AF, Paulic K, Afable M 2nd, Englehaupt R, Maciejewski JP.

Am J Hematol. 2011 Jan;86(1):102-3. doi: 10.1002/ajh.21891.

7.

Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.

Scherman E, Malak S, Perot C, Gorin NC, Rubio MT, Isnard F.

Leukemia. 2012 Apr;26(4):822-4. doi: 10.1038/leu.2011.284. Epub 2011 Oct 14. No abstract available.

PMID:
21997572
8.

[Myelodysplastic syndromes (MDS)].

Kizaki M.

Nihon Rinsho. 2014 Jun;72(6):1079-86. Japanese.

PMID:
25016808
9.

New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

Loiseau C, Ali A, Itzykson R.

Exp Hematol. 2015 Aug;43(8):661-72. doi: 10.1016/j.exphem.2015.05.014. Epub 2015 Jun 27. Review.

PMID:
26123365
10.

Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?

Platzbecker U, Germing U.

Leukemia. 2013 Sep;27(9):1813-9. doi: 10.1038/leu.2013.140. Epub 2013 May 6. Review.

PMID:
23644421
11.

Myelodysplastic syndromes (MDS).

Klimek V.

Best Pract Res Clin Haematol. 2015 Mar;28(1):1-2. doi: 10.1016/j.beha.2014.11.007. Epub 2014 Nov 29. No abstract available.

PMID:
25659724
12.

New agents in the treatment of MDS.

List AF.

Clin Adv Hematol Oncol. 2005 Nov;3(11):832-4. No abstract available.

PMID:
16491623
13.

Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Prebet T, Charbonnier A, Gelsi-Boyer V, Mozziconacci MJ, Blaise D, Vey N.

Leuk Lymphoma. 2013 Jul;54(7):1538-40. doi: 10.3109/10428194.2012.744455. Epub 2012 Nov 29. No abstract available.

PMID:
23110702
14.

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Zeidan AM, Kharfan-Dabaja MA, Komrokji RS.

Curr Opin Hematol. 2014 Mar;21(2):123-30. doi: 10.1097/MOH.0000000000000016. Review.

15.

Azacitidine in lower-risk myelodysplastic syndromes.

Santini V.

Leuk Res. 2009 Dec;33 Suppl 2:S22-6. doi: 10.1016/S0145-2126(09)70230-9.

PMID:
20004794
16.

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.

Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N.

Cancer. 2008 Oct 1;113(7):1596-604. doi: 10.1002/cncr.23789.

17.

Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes.

Steensma DP.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1145-7. doi: 10.1016/j.bbmt.2012.05.004. Epub 2012 May 15. No abstract available.

18.

Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.

Fenaux P, Ades L.

Leuk Res. 2009 Dec;33 Suppl 2:S7-11. doi: 10.1016/S0145-2126(09)70227-9. Review.

PMID:
20004796
19.

Lenalidomide in myelodysplastic syndromes: where do we go from here?

Sirulnik LA, Stone RM.

Curr Hematol Malig Rep. 2008 Jan;3(1):5-9. doi: 10.1007/s11899-008-0002-1.

PMID:
20425440
20.

[Myelodysplastic syndromes: therapeutic advances and promising future].

Nomdedeu B.

Med Clin (Barc). 2008 Oct 18;131(13):500-2. Spanish. No abstract available.

PMID:
19007578
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk